for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Astellas Pharma Inc

4503.T

Latest Trade

1,712.00JPY

Change

-3.50(-0.20%)

Volume

1,044,000

Today's Range

1,705.00

 - 

1,722.50

52 Week Range

1,356.00

 - 

1,873.50

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,715.50
Open
1,714.50
Volume
1,044,000
3M AVG Volume
116.75
Today's High
1,722.50
Today's Low
1,705.00
52 Week High
1,873.50
52 Week Low
1,356.00
Shares Out (MIL)
1,886.11
Market Cap (MIL)
3,240,276.00
Forward P/E
16.59
Dividend (Yield %)
2.22

Next Event

Q2 2020 Astellas Pharma Inc Earnings Release

Latest Developments

More

EU Medicines Agency Says CHMP Recommends Granting Marketing Authorisation For AstraZeneca's Drug Qtrilmet

Fibrogen Says Evrenzo Approved By Japan’s Ministry of Health, Labour and Welfare

Astellas Pharma Says Japan's Ministry Of Health, Labour And Welfare Approved Evrenzo(Roxadustat)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Astellas Pharma Inc

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

Industry

Major Drugs

Contact Info

2-5-1, Nihombashihon-cho

+81.3.32443000

https://www.astellas.com/jp/

Executive Leadership

Yoshihiko Hatanaka

Chairman of the Board, Chairman of the Board of Directors, Representative Director

Kenji Yasukawa

President, Chief Executive Officer, Representative Director

Naoki Okamura

Vice President, Representative Director

Nobuaki Tanaka

Senior Executive Officer, Chief Director of Sales

Akihiko Iwai

Senior Executive Officer, Chief Director of Research

Key Stats

2.17 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

1.3K

2018

1.3K

2019

1.3K

2020(E)

1.2K
EPS (JPY)

2017

103.690

2018

81.110

2019

115.050

2020(E)

103.472
Price To Earnings (TTM)
14.54
Price To Sales (TTM)
2.47
Price To Book (MRQ)
2.59
Price To Cash Flow (TTM)
11.15
Total Debt To Equity (MRQ)
13.85
LT Debt To Equity (MRQ)
10.37
Return on Investment (TTM)
15.65
Return on Equity (TTM)
11.93

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up